Clinical Trials on Dermatologic in South Africa

Total 1024 results

IDinsight
Reach Digital Health (formerly Praekelt.org)

Recruiting

Testing Content Delivery Models for MomConnect (MQR)

Hematological Diseases | Breastfeeding | Immunization Coverage

South Africa
Catalyst Biosciences

Completed

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Hemophilia B

South Africa
Swiss Federal Institute of Technology
University of Stellenbosch

Completed

Stable Iron Isotope Method in HIV+ and HIV- Children

Iron-deficiency

South Africa
Swiss Federal Institute of Technology
University of Stellenbosch

Recruiting

Potential of Prebiotic Galacto-oligosaccharides in Improving Efficacy and Safety of Oral Iron Supplementation in HIV-infected Children

HIV | Iron Deficiency

South Africa
North-West University, South Africa
Medical Research Council, South Africa; Swiss Federal Institute of Technology; Unilever R...

Completed

The Effects of Iron and Omega-3 Fatty Acid Supplementation on Cognition and Immune Function in Iron Deficient Children (FeFA)

Anemia | Iron Deficiency

South Africa
University of Cape Town

Completed

Iron Deficiency Anaemia in Pregnant Patients Presenting for Antenatal Care

Iron Deficiency Anemia of Pregnancy

South Africa
University of Cape Town

Completed

Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients (EPIC-1)

Hyperglycemia | Anemia, Iron Deficiency

South Africa
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Anemia

South Africa
BioCryst Pharmaceuticals

Recruiting

Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

South Africa, Malaysia
BioCryst Pharmaceuticals

Completed

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Austria, South Africa
University of Cape Town
University of Stellenbosch; University of KwaZulu

Recruiting

South African Paediatric Surgical Outcomes Study 2 (SAPSOS2)

Iron Deficiency Anemia | Anaemia | Iron | Prospective Studies | Paediatric Surgery | Interventional Studies

South Africa
Bayer

Completed

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (MATCHBOX)

Hemophilia A | Hemophilia B

South Africa, Poland, United Kingdom
Novo Nordisk A/S

Completed

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

India, Morocco, South Africa, Oman
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
BioCryst Pharmaceuticals

Terminated

A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

United Kingdom, Austria, South Africa
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy (REDEEM-2)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Malaysia, South Africa, Korea, Republic of
AbbVie

Terminated

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Korea, Republic of, South Africa
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (GENEr8-AAV5+)

Hemophilia A | Gene Therapy | Blood Disorder | Clotting Disorders

Taiwan, Korea, Republic of, United Kingdom, South Africa
Vega Therapeutics, Inc

Recruiting

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease

Von Willebrand Diseases

United States, Austria, South Africa, United Kingdom
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Sanofi

Completed

A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen (Grano-Tax)

Neoplasms (no Otherwise Specified)

South Africa
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
University of Sydney
University of Roma La Sapienza; Australasian Bone Marrow Transplant Recipient... and other collaborators

Recruiting

Prophylactic Early PN in HPT/BMT

Hematologic Neoplasms

Australia, New Zealand
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
Novartis Pharmaceuticals

Terminated

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (MACS1574)

Myelodysplastic Syndrome | Transfusional Iron Overload

Spain, France, Italy, South Africa
Medical University of South Carolina

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

Hematological Malignancies

United States
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Bulgaria, Ukraine, Czechia, United States, Georgia, South Africa
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Trauma | Acquired Bleeding Disorder

Germany, Austria, Israel, France, Canada, Singapore, South Africa, Australia, United Kingdom
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Hutchison Medipharma Limited
Iqvia Pty Ltd

Unknown

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancies

Australia
AstraZeneca

Completed

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (HESTIA 1)

Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease

United States, Canada, United Kingdom, South Africa, Lebanon, Kenya
BioCryst Pharmaceuticals

Active, not recruiting

Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Hungary, France, Spain, Malaysia, South Africa, Korea, Republic of
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Keros Therapeutics, Inc.
IQVIA Biotech

Recruiting

Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

Myelofibrosis

Australia
Senesco Technologies, Inc.

Unknown

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Multiple Myeloma | Plasma Cell Leukemia | Multiple Myeloma in Relapse | Mantle Cell Lymphoma in Relapse | Diffuse Large B Cell Lymphoma in Relapse | Other B Cell Lymphoma in Relapse

United States, South Africa
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Neutropenia

Australia
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Sickle Cell Anemia

Turkey, United States, Germany, Canada, United Kingdom, Israel, South Africa
University of Sheffield

Completed

Investigating Compassion-Based Guided Self-Help for Depression in People With Skin Conditions

Depression | Dermatologic Disease

United Kingdom
BioAge Labs, Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

Acute Posthemorrhagic Anemia

Australia
Mayne Pharma International Pty Ltd

Completed

Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis

Neutropenia

Australia
Accenture

Completed

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Hematologic Malignancies

Korea, Republic of, Australia, Canada
BioMarin Pharmaceutical

Recruiting

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors (GENEr8-INH)

Hemophilia A With Inhibitor | Hemophilia A With Anti Factor VIII

United States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
BioAge Labs, Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

Anemia

Australia
Mayne Pharma International Pty Ltd

Completed

Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg

Neutropenia

Australia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Pure Red-cell Aplasia

United Kingdom, Sweden, South Africa, Brazil, Canada, Germany, Norway, Thailand
Kartos Therapeutics, Inc.

Recruiting

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
Christian Medical College, Vellore, India

Unknown

Musculoskeletal Function in Hemophilia

Hemophilia

India, Argentina, Brazil, Egypt, Iran, Islamic Republic of, Singapore, South Africa, Thailand, Venezuela

Clinical Trials on Dermatologic in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations